KRYSTAL BIOTECH INC
NASDAQ: KRYS (Krystal Biotech, Inc.)
Last update: yesterday, 8:24AM311.50
-8.63 (-2.70%)
| Previous Close | 320.13 |
| Open | 318.91 |
| Volume | 270,034 |
| Avg. Volume (3M) | 287,145 |
| Market Cap | 9,220,037,632 |
| Price / Earnings (TTM) | 39.04 |
| Price / Earnings (Forward) | 46.95 |
| Price / Sales | 23.53 |
| Price / Book | 7.44 |
| 52 Weeks Range | |
| Earnings Date | 2 Nov 2026 |
| Profit Margin | 37.17% |
| Operating Margin (TTM) | 41.03% |
| Diluted EPS (TTM) | 4.18 |
| Quarterly Revenue Growth (YOY) | 94.90% |
| Quarterly Earnings Growth (YOY) | 3,734.00% |
| Total Debt/Equity (MRQ) | 0.98% |
| Current Ratio (MRQ) | 9.65 |
| Operating Cash Flow (TTM) | 138.50 M |
| Levered Free Cash Flow (TTM) | 76.74 M |
| Return on Assets (TTM) | 8.66% |
| Return on Equity (TTM) | 13.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Krystal Biotech, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | 5.0 |
| Financial Health | 5.0 |
| AI Insight | NA |
| Weighted Average | 1.63 |
Select this tab to load the latest available analysis.
|
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.88% |
| % Held by Institutions | 104.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vestor Capital, Llc | 30 Jun 2026 | 700,914 |
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |